Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz's Somatropin Becomes First Biosimilar Approved In Japan

This article was originally published in The Pink Sheet Daily

Executive Summary

Japan's Ministry of Health, Labor and Welfare approved the recombinant human growth hormone injection less than a year after releasing draft guidelines and three months after Sandoz/Novartis submitted the application.

You may also be interested in...



Korea FDA Gears Up To Release Biosimilar Guidelines Modeled After EU Rules

SEOUL - South Korea's FDA is getting ready to release - possibly by the end of May - an initial version of guidelines for approval and registration of biosimilars modeled after European Union rules. The guidelines will wrap up KFDA's year-long drive to set up a regulatory framework for the new breed of follow-on biologics

Korean LG Life Sciences Plans BLA Submission For Biosimilar Somatropin To U.S. FDA

SEOUL - South Korea's LG Life Sciences completed its Phase III clinical trial of its slow-release recombinant human growth hormone somatropin weekly injection for treating adults with growth hormone deficiency, and is getting its biologics license application ready for U.S. FDA for the new formulation

Japan Chemical Research, Kissei Submit First Biosimilar Application In Japan

TOKYO - Japan Chemical Research Pharmaceutical of Kobe in Western Japan and Kissei Pharmaceutical of Matsumoto City in central Japan have applied to the Ministry of Health, Labor and Welfare for marketing what is expected to be Japan's first biosimilar therapeutic, spokespersons for the two companies told PharmAsia News Nov. 26

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069622

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel